TheraTech (THRT) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TheraTech (THRT)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ying Wang who wrote (32)	1/14/1997 9:29:00 AM
From: Robert Stewart	of 125

This is a news release I have just picked up: Lilly (LLY), TheraTech in collaborative pact INDIANAPOLIS, Jan 14 (Reuter) - Eli Lilly and Co and TheraTech Inc (THRT) said Tuesday they entered a multi-product collaborative agreement to develop and market peptide drugs using TheraTech's patented oral transmucosal delivery system. Lilly said its peptide drugs are at various stages of preclinical and clinical development and a majority are in the endocrine area. Under the agreement, TheraTech will receive initial fees, funding for research, milestone payments and royalties on potential product sales. Lilly will receive exclusive commercialization rights for the oral transmucosal delivery of certain peptide drugs. The TheraTech transmucosal delivery system is a small, adhesive-backed tablet that is placed in the mouth between the lip and gum. As it slowly dissolves, it delivers peptide drugs directly into a patient's bloodstream through the mucous membrane of the mouth. TheraTech, headquartered in Salt Lake City, Utah, develops products based on controlled-release drug delivery technologies. Lilly is a global research-based pharmaceutical corporation. ((Reuters Chicago Newsdesk (312) 408-8787)) Rtr 08:17 01-14-97 (Eastern Standard Time)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next